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The choroid plexus-cerebrospinal fluid interface in 
Alzheimer’s disease: more than just a barrier
Choroid Plexus-Cerebrospinal Fluid (CSF) 
System
The choroid plexus is a highly vascularized structure which 
hangs in the brain ventricles and contains a monolayer of 
choroid plexus epithelial (CPE) cells. These CPE cells form 
the blood-cerebrospinal fluid barrier (BCSFB). In contrast to 
the blood-brain barrier (BBB), which is formed by endothe-
lial cells at the level of brain capillaries, CPE cells are located 
on top of fenestrated capillaries. Both the CPE cells at the 
BCSFB and endothelial cells at the BBB are interconnected 
with tight junctions which restrict the entry of molecules 
and pathogens from blood into brain. The BCSFB apical sur-
face has half the area of the BBB surface due to the presence 
of microvilli at the apical side of the CPE cells, which implies 
that the BCSFB also has a vital role in brain homeostasis. 
A major task of the CPE cells is CSF production. CSF has 
several established functions: it protects the brain from blood 
pressure changes and mechanical trauma, enables transport 
of various molecules through the entire central nervous sys-
tem (CNS) and facilitates the removal of toxins and waste 
products. Consequently, the choroid plexus-CSF system plays 
an active role in physiological processes such as development, 
repair and maintenance of brain homeostasis. Additionally, 
this structure is important as an inflammatory sensor that 
detects signals originating from both the peripheral and the 
central nervous system (Vandenbroucke et al., 2012; Brkic 
et al., 2015b). Subsequently, the CPE cells can transmit the 
inflammatory signal, e.g., by the production of cytokines and 
chemokines. Additionally, the choroid plexus functions as a 
gateway to the brain by secreting chemoattractants that facil-
itate the entry of different peripheral immune cells into the 
brain (Demeestere et al., 2015). Although the brain was orig-
inally considered as an immune privileged site, the presence 
of T lymphocytes has been reported in CSF, and the choroid 
plexus was shown to have a niche of effector CD4(+) mem-
ory cells with a T-cell receptor repertoire specific to CNS 
antigens (Baruch et al., 2013). Next to their barrier function, 
CPE cells express on their membranes polarized and specific 
transport systems that enable them to control the traffick-
ing of various brain nutrients, such as amino acids, peptide 
hormones, nucleosides and ions. Finally, role of CPE in the 
clearance of toxic molecules and drugs from the brain has 
been long established (de Lange, 2004).
Choroid Plexus-CSF System in Aging and 
Neurodegenerative Disorders
Due to the increasing number of elderly in the world’s popu-
lation, much attention has been recently given to the study of 
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also been noticed (Marques et al., 2013). Additionally, Aβ 
deposits were also observed in CPE cells in AD (Dietrich et 
al., 2008). In our work, using a mouse model of AD based on 
direct injection of Aβ1–42 oligomers into the brain ventricles, 
we confirmed that Aβ1–42 induces alterations in the cuboi-
dal shape of CPE cells, and we also observed a decrease in 
the expression of tight junction components (Brkic et al., 
2015b). Moreover, these changes were associated with in-
creased leakiness of the BCSFB, potentially aggravating dis-
ease progression. Interestingly, it was speculated almost two 
decades ago that BCSFB dysfunction occurs in AD patients 
(Hampel et al., 1997), and this was recently confirmed by 
Bergen et al. (2015) who showed decreased expression of 
tight junction components in diseased CPE. In our mouse 
study, we showed that matrix metalloproteinases (MMPs), 
which have been implicated in several neurodegenerative 
diseases (Brkic et al., 2015a), are key players in the Aβ1–42 
oligomer-induced barrier disruption and that barrier in-
tegrity could be preserved by applying a broad-spectrum 
MMP inhibitor or by abolishing MMP-3 in mice. So far, 
there are no clear data from humans about the role of 
MMPs in BCSFB breakdown in AD, although several au-
thors reported increased presence of specific MMPs in CSF, 
plasma and serum of AD patients (Horstmann et al., 2010; 
Bjerke et al., 2011). However, the data are not consistent, 
and the prospect for therapeutic MMP inhibition as an AD 
treatment remains precarious (Brkic et al., 2015a). Indeed, 
MMPs play pivotal roles in many physiological conditions, 
including tissue repair, which could make their inhibition 
harmful (Vandenbroucke and Libert, 2014).
In accordance with the theory of aging as an inflammatory 
disease, various proinflammatory cytokines, such as TNF-α, 
were found in CSF of patients suffering from AD (Tarkowski 
et al., 2003). Likewise, we observed a significant increase in 
gene expression of the proinflammatory mediators Il1β, Il6, 
and Inos in CPE cells and increased cytokine levels in CSF; 
these trigger MMP activity and lead to opening of the bar-
rier (Brkic et al., 2015b). Other researchers have identified 
an important role for the choroid plexus-CSF system in the 
clearance of toxic Aβ species from the brain into CSF via 
specific transporters (e.g., lipoprotein receptor-related pro-
tein 2; LRP-2) and secretion of transthyretin (TTR). Both 
LRP-2 and TTR can bind Aβ and facilitate its removal from 
the brain, thereby preventing Aβ plaque formation. Interest-
ingly, TTR was found to be decreased in CSF in aging and in 
AD (Serot et al., 1997; Chen et al., 2005). In contrast how-
ever, recent findings showed no evidence of changes in CP 
TTR production levels in healthy or AD individuals (Bergen 
et al., 2015).
The CP serves as a selective entry gate for leukocytes 
into the CNS by surface expression of adhesion molecules 
that facilitate leukocyte transmigration (Demeestere et al., 
2015). Recently, Baruch et al. observed that during aging 
and AD, nitric oxide (NO) levels were upregulated also in 
CP. These increased NO levels serve as a negative regulator 
of the CP gateway activity for immune cell infiltration into 
the CNS. Similarly, the 5XFAD mouse, a transgenic model 
aging and age-related diseases, including neurodegenerative 
disorders. Chronic neuroinflammation has been observed 
in aging individuals, and in neurodegenerative diseases it 
leads to aggravation of the disease. Recently, it was reported 
that aging is associated with increased type I interferon de-
pendent gene expression in the choroid plexus and that this 
expression interferes with normal brain function (Baruch et 
al., 2014).
The most prevalent neurodegenerative disorder, Alzhei-
mer’s disease (AD), is characterized by progressive loss of 
cognitive abilities and by brain atrophy accompanied by 
accumulation of amyloid β (Aβ) plaques in the brain pa-
renchyma and neurofibrillary tangles, and aggregates of 
hyperphosphorylated tau protein in the neurons. While the 
BBB has been extensively studied in AD, the BCSFB has been 
largely understudied. Recent studies suggest that the choroid 
plexus-CSF system exhibits morphological changes and a 
functional decline with aging, which is believed to be exacer-
bated in AD (Figure 1). The most prominent changes include 
anomalies in CSF production and general turnover, and 
these have been observed in humans and in animal models 
of age-related diseases (Redzic et al., 2005). Changes in CPE 
cell metabolism such as decline in metabolic and enzymatic 
activity are evident. The cytoplasm of CPE cells is filled with 
a variety of species, such as amyloid Biondi bodies (com-
plex filamentous ring-like structures of 8–15 nm diameter 
associated with lipid droplets), psammoma bodies (calcified 
intracellular inclusion structures), and lipofuscin (yellow or 
brown intracellular structures composed of lipid molecules 
and usually residues of lysosomal digestion process). Cal-
cification and thickening of the basement membrane have 
Figure 1 Schematic representation of choroid plexus epithelial (CPE) 
cells. 
The left side represents healthy CPE cells, reflected by the presence of 
tight junctions, secretion of cerebrospinal fluid (CSF), neurotrophins, 
nutrients, transthyretin (TTR), etc. These cells have numerous trans-
porters at their apical and basolateral sides. The right side represents 
CPE cells in Alzheimer’s disease, as reflected by the alteration of altered 
tight junctions, reduced secretion of CSF and neurotrophins, and ac-
cumulation of toxic molecules inside the cell. Additionally, expression 
of several transporters is altered, e.g., lipoprotein receptor-related pro-
teins 1 and 2 (LRP-1 and -2) and P-glycoprotein (P-gp). MMPs: Matrix 
metalloproteinases.
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nutrients, neurotrophins, 
TTR, etc.
Reduced CSF production, 
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of AD, is less able to reduce immune cell trafficking to the 
CNS. Interestingly, administration of NO scavenger mole-
cules in these animals induced NFκB/p65 pathway activa-
tion and restored CP gateway activity (Baruch et al., 2015). 
Using the same mouse model, these authors also showed 
that depletion of Foxp3(+) regulatory T cells or inhibi-
tion of their activity by pharmaceutical compounds can 
alleviate plaque pathology and neuroinflammation. This 
suggests that targeting Treg-mediated systemic immuno-
suppression is a plausible strategy for treating AD (Baruch 
et al., 2015).
Regeneration of the Brain with CPE Cells
Because AD is a complex neurodegenerative disorder, elim-
inating or inhibiting the production of toxic species like Aβ 
alone is not sufficient to treat it, and emphasis must also 
be placed on the regenerative aspects of the damaged brain 
regions. Several studies have shown the induction of neuro-
trophins close to damaged sites in the brain, and injection 
of neurotrophins near the damaged areas was shown to 
improve the recovery process. Transplantation of neurotro-
phin releasing cells might provide sustainable continuous 
release of these molecules. Studies on the choroid plexus 
and its effect on the brain have pointed to the possibility 
of rejuvenating the damaged brain regions (Thanos et al., 
2010). For example, Borlongan et al. (2004b) were the first 
to demonstrate that the choroid plexus can produce neuro-
trophic factors such as glial cell-derived neurotrophic factor 
(GDNF), brain-derived neurotrophic factor (BDNF), and 
nerve growth factor (NGF). Conditioned medium collected 
from primary CPE cultures can protect serum deprived cor-
tical neurons in a dose dependent manner. The same authors 
also performed intracranial transplantation of porcine CPE 
cells in rats, and this improved the behavioral performance 
and decreased the volume of infarction in the rodent stroke 
model (Borlongan et al., 2004b). Similarly, Bolos et al. 
showed that cultured CPE cells treated with oligomeric Aβ 
lead to increased proliferation and differentiation of neuro-
nal progenitor cells. Moreover, transplantation of CPE cells 
into the APP/PS1 mouse brain induced a significant reduc-
tion in brain Aβ and p-tau levels and this revealed improved 
spatial and non-spatial memory in APP/PS1 mice (Bolos 
et al., 2014). In another study, CPE cells extracted from rat 
brain were encapsulated and transplanted into the brain of 
Aβ injected mice. The grafted CPE cells significantly reduced 
apoptosis, gliosis and oxidative stress and increased neuro-
genesis. Moreover, the mice’s long-term memory improved, 
indicating that CPE cells might be considered for cell thera-
py in AD (Aliaghaei et al., 2015).
CPE cells are also involved in Aβ clearance. Aβ is taken up 
by CPE cells for degradation, but since CPE lysosomal func-
tion is compromised in AD, Aβ accumulates rather than be-
ing cleared. Like the BBB, the BCSFB possesses transporters 
that can transport Aβ from CSF to blood, i.e., LRP-1, LRP-2/
megalin, receptors for advanced glycation end (RAGE) and 
P-glycoprotein (P-gp). However, several of these transporters 
are compromised in AD, which contributes to Aβ accumula-
tion in the brain (Mesquita et al., 2012).
The above-mentioned findings shed light on the neuro-
protective capacity of CPE cells and on their potential use in 
cell therapy to treat neurodegenerative diseases. Moreover, 
CPE cell transplantation studies conducted in other neuro-
degenerative diseases, such as Huntington’s disease, were also 
successful (Emerich and Borlongan, 2009). Furthermore, 
choroid plexus cell transplantation also alleviated other 
pathological brain conditions, such as cerebral ischemia in 
adult rats (Borlongan et al., 2004a).
The presence of stem cells in the brain near the subventric-
ular zone (SVZ) was reported recently, but the mechanisms 
regulating their differentiation and migration into the CNS 
is not clear. However, the proximity of the pluripotent stem 
cells to the choroid plexus-CSF system suggests that CPE-de-
rived growth factors are required for the maintenance and 
differentiation of the stem cell lineage. Interestingly, Ide et al. 
(2001) reported that choroid plexus ependymal cells (CPEC) 
isolated from the fourth ventricle can induce axonal growth 
when transplanted into the dorsal funiculus of rat spinal 
cord. Results from the same group demonstrated that one 
week after grafting green fluorescent protein (GFP)-positive 
CPEC cells at the injured spinal cord site, some of the GFP-
CPEC cells became also positive for the glial fibrillary acidic 
protein (GFAP), a marker for astrocytes. In support of those 
results, CPE cells were shown to have the capacity to differ-
entiate into neural precursor cells after focal cerebral isch-
emia (Li et al., 2002). Although these studies are preliminary, 
they point to the possibility of rejuvenating the damaged 
brain via the choroid plexus. However, the biologically active 
factors that are secreted by the CPE cells at the grafted site 
have first to be identified.
Conclusion
The choroid plexus plays a pivotal role in brain homeostasis. 
Indeed, the structure, function and location of the choroid 
plexus-CSF system provides it with a significant influence on 
physiological and pathological CNS functioning. CPE cells 
are tightly connected, which prevents uncontrolled leakage 
from blood into the CSF and enables the choroid plexus to 
control inflammatory cell influx into the brain. CPE cells 
contain numerous transporters and can actively secrete 
molecules that spread the inflammatory response into the 
brain. Moreover, CPE cells also play a significant role in the 
clearance of toxic molecules such as Aβ. In aging and AD, 
CPE cell functionality is heavily affected, reflected by loss of 
structural integrity and changes in secretory activity, and this 
might play a central role in disease initiation or exacerba-
tion of disease progression. This indicates the possibility of 
rejuvenating CPE cells to restore their functions and thereby 
treat neurodegenerative diseases such as AD by targeting the 
choroid plexus‒CSF system.
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